GREENWOOD VILLAGE, Colo., May 14, 2012 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NASDAQ: AMPE), a biopharmaceutical company conducting clinical trials on its three lead drugs (Ampion, Optina and Zertane), licensing distribution of those drugs and engaged in further drug development), will hold a webcast on Wednesday, May 16, 2012, at 4:15 p.m. EDT. Management will outline the Company's 2012 progress, provide a detailed review for each of its three lead products and update the status of licensing and collaboration efforts.
United States: 800.295.3991
The call also can be accessed at www.ampiopharma.com.
United States: 888 286.8010
International: 617 801.6888
The replay will be posted approximately two hours after the completion of the live event, and it will be available for 7 days. Ampio will post a replay of the May 16, 2012 call on its website.
About Ampio Pharmaceuticals
Ampio Pharmaceuticals, Inc. develops innovative proprietary drugs for metabolic disease, eye disease, kidney disease, inflammation, CNS disease, and male sexual dysfunction. The product pipeline includes new uses for previously approved drugs and new molecular entities ("NMEs"). By concentrating on development of new uses for previously approved drugs, approval timelines, costs and risk of clinical failure are reduced because these drugs have strong potential to be safe and effective while their shorter development times can significantly increase near term value. A key strategy includes actively exploring partnership, licensing and other collaboration opportunities to maximize Ampio's product development programs. For more information about Ampio, please visit our website, www.ampiopharma.com.
Investor Relations, Ampio Pharmaceuticals, Inc. 720-437-6500
SOURCE Ampio Pharmaceuticals, Inc.